Trevena Announces Presentations during PAINWeek® 2017
September 07 2017 - 4:01PM
– Hospital charge database study shows high
prevalence of opioid-related adverse events in key surgical
specialties despite use of multimodal analgesia –
Trevena, Inc. (NASDAQ:TRVN) today announced results from three
poster presentations given during PAINWeek® 2017, held at The
Cosmopolitan Hotel in Las Vegas, Nevada, September 5-9. The
presentations described new data highlighting the burden of
opioid-related adverse events in hospital patients who require
intravenous (IV) opioids to manage their pain, and identified
specific procedures and patient characteristics associated with
elevated risk of acute opioid-related adverse events.
“These hospital database and survey data show that conventional
IV opioids remain a necessary component of acute postoperative pain
management, despite their many drawbacks,” said Peter Whang, M.D.,
FACS, Associate Professor of Orthopaedics & Rehabilitation at
Yale University School of Medicine. ”The findings highlight that
patients who most require IV opioids, but are at elevated risk from
opioid-related adverse events, reflect an important unmet need for
new analgesic options.”
Two of the poster presentations described the results of a study
assessing patient characteristics and other predictors of
post-operative nausea/vomiting (PONV) and opioid-induced
respiratory depression (OIRD) associated with the use of
conventional parenteral opioids to manage acute postoperative
pain. The study assessed 592,127 hospital stays in the
Premier Perspectives® Hospital Database for general/colorectal,
orthopedic, OB/GYN, cardiothoracic/vascular, and urologic
procedures. These procedures are associated with severe and
prolonged pain, and with patient risk factors that have been
suggested to elevate the risk for opioid-related adverse
events. Despite the widespread use of multimodal analgesia,
substantial doses of parenteral opioids were administered to these
patients, ranging from 27 mg to 79 mg of morphine equivalents per
day. This was associated with high rates of OIRD, with
incidence from 3% to 17% across the different surgical
specialties. Obesity, respiratory conditions, and sleep apnea
were significantly associated with an increased likelihood of
OIRD. The study also found high rates of PONV, with incidence
ranging from 44% to 72%. Female patients and younger patients
were found to have an increased likelihood of PONV. The prevalence
of these adverse events was higher in this database’s population
than broader hospitalized patient populations studied in previous
publications.
A third poster described a recent survey of 501 physicians on
their practice patterns in managing acute postoperative pain.
Results indicate that both patient characteristics (such as chronic
opioid use, age, and respiratory comorbidities) and opioid-related
adverse events (such as nausea, vomiting, and respiratory
depression) remain a common challenge in postoperative pain
management and play a key role in influencing treatment decisions,
particularly in high-risk patients.
Poster presentations: Thursday, September 7, 6:30 – 8:30
p.m. PDT
- Poster Number 4: Predictors of Post-Operative Nausea or
Vomiting Associated with Opioid Treated Acute Postoperative Pain.
Anthony J. Senagore, Ashraf S. Habib, Kellie Morland, Sheikh Usman
Iqbal, David Soergel, Marla Kugel, Sizhu Liu, and Gary
Oderda
- Poster Number 5: Predictors of
Opioid-induced Respiratory Depression Associated with Acute
Postoperative Pain Treatment. Ashraf S. Habib, Anthony J. Senagore,
Kellie Morland, Sheikh Usman Iqbal, David Soergel, Marla Kugel,
Sizhu Liu, and Gary Oderda
- Poster Number 96: Physician Practice Patterns and Treatment
Challenges in Acute Postoperative Pain Management. Tong-Joo Gan,
Robert Epstein, Barbara Menzel, Megan Leone-Perkins, Tehseen
Salimi, Sheikh Usman Iqbal, and Peter G. Whang
Abstracts may be accessed online at:
http://conference.painweek.org/scientificposters.
About Trevena
Trevena, Inc. is a biopharmaceutical company developing
innovative therapies based on breakthrough science to benefit
patients and healthcare providers confronting serious medical
conditions. The Company has discovered four novel and
differentiated drug candidates, including OLINVO™ (oliceridine
injection), for the management of moderate-to-severe acute pain,
TRV250, for the treatment of acute migraine, and TRV734 for pain.
The Company maintains an early stage portfolio of drug discovery
programs.
Cautionary note on forward looking
statements
Any statements in this press release about future expectations,
plans and prospects for the Company, including statements about the
Company’s strategy, future operations, clinical development of its
therapeutic candidates, plans for potential future product
candidates and other statements containing the words “anticipate,”
“believe,” “estimate,” “expect,” “intend,” “may,” “plan,”
“predict,” “project,” “suggest,” “target,” “potential,” “will,”
“would,” “could,” “should,” “continue,” and similar expressions,
constitute forward-looking statements within the meaning of The
Private Securities Litigation Reform Act of 1995. Actual results
may differ materially from those indicated by such forward-looking
statements as a result of various important factors, including: the
status, timing, costs, results and interpretation of the Company’s
clinical trials, and the expected timing of the NDA submission for
OLINVO; the uncertainties inherent in conducting clinical trials;
expectations for regulatory approvals; availability of funding
sufficient for the Company’s foreseeable and unforeseeable
operating expenses and capital expenditure requirements;
uncertainties related to the Company’s intellectual property; other
matters that could affect the availability or commercial potential
of the Company’s therapeutic candidates, including whether IV
opioids remain a necessary component of acute postoperative pain
management; and other factors discussed in the Risk Factors set
forth in the Company’s Annual Report on Form 10-K and Quarterly
Reports on Form 10-Q filed with the Securities and Exchange
Commission (SEC) and in other filings the Company makes with the
SEC from time to time. In addition, the forward-looking statements
included in this press release represent the Company’s views only
as of the date hereof. The Company anticipates that subsequent
events and developments may cause the Company’s views to change.
However, while the Company may elect to update these
forward-looking statements at some point in the future, it
specifically disclaims any obligation to do so, except as may be
required by law.
Contacts
Investors:
Jonathan Violin, Ph.D.
Vice President, Corporate Strategy & Investor Relations
610-354-8840 x231
jviolin@trevena.com
Media:
Public Relations
PR@trevena.com
Trevena (NASDAQ:TRVN)
Historical Stock Chart
From Aug 2024 to Sep 2024
Trevena (NASDAQ:TRVN)
Historical Stock Chart
From Sep 2023 to Sep 2024